As for the missense mutations that affect the binding of FIXa with FVIIIa, a bi-specific antibody, similar to those used in hemophilia A [102], can be developed to treat hemophilia B. In brief, understanding the molecular mechanisms of FIX deficiency may improve future patient diagnosis and clinical decision making, and lead to precision medicine for hemophilia B patients. This evidence concerns the gene F9 and hemophilia A.